Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
DBV Technologies S.A. develops treatment options for food allergies and other immunologic conditions as a late-stage biopharmaceutical company. Company updates center on the proprietary VIASKIN® patch technology, epicutaneous immunotherapy, and the VIASKIN Peanut program for peanut-allergic toddlers and children.
Recurring developments include clinical data from the Phase 3 VITESSE study, annual and quarterly financial results, financing and warrant-related capital actions, leadership and governance changes, share and voting-rights disclosures under French market rules, and market information tied to DBVT American Depositary Shares.
DBV Technologies (Nasdaq: DBVT), a late-stage biopharmaceutical company, will participate in 1-on-1 investor meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, in Miami, FL.
CEO Daniel Tassé will not attend the previously scheduled fireside chat due to travel disruption.
DBV Technologies (Nasdaq:DBVT) will present new data on its VIASKIN Peanut Patch at the EAACI Congress 2026. Phase 3 VITESSE subgroup results in children aged 4–7 with asthma, other food allergies or atopic dermatitis showed statistically significant efficacy vs placebo, with responder rates broadly around 47% vs 15%. DBV will also preview the Phase 2 THRIVE study design in approximately 250 infants aged 6–12 months, which will evaluate ad lib peanut consumption after three years of epicutaneous immunotherapy treatment.
DBV Technologies (Nasdaq: DBVT) announced that CEO Daniel Tassé will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference.
The session is scheduled for June 9, 2026, at 9:20 AM ET in Miami, with a live webcast and 90-day replay on the company’s investor website.
DBV Technologies (NASDAQ:DBVT) reported its share capital and voting rights as of May 31, 2026, under Article 223-16 of the AMF General Regulations.
The company had 296,061,497 shares, with a total gross voting rights of 296,061,497 and a total net voting rights of 295,906,088.
DBV Technologies (Nasdaq: DBVT) held its 2026 Combined General Meeting in Châtillon, France, on June 3, 2026. The meeting was chaired by Michel de Rosen, Chairman of the Board of Directors.
Shareholders approved all resolutions submitted by the Board. Detailed resolutions and voting results are available on the company’s website.
DBV Technologies (Nasdaq: DBVT) reported the first participant screened in THRIVE, a Phase 2, single-arm, open-label study of the VIASKIN Peanut Patch in infants 6–12 months with peanut allergy.
Infants receive daily patch treatment for 36 months, followed by a 12‑month period assessing ad lib peanut consumption.
DBV Technologies (Nasdaq:DBVT) will hold its Combined General Meeting on June 3, 2026, at 10:00 a.m. CEST at its Châtillon headquarters. Shareholders can access the agenda, draft resolutions and voting instructions on the company website and request documents by email until May 29, 2026. The meeting will be webcast live, subject to technical conditions, and a replay will be posted within seven business days for at least the minimum required legal period.
DBV Technologies (Nasdaq: DBVT) announced that CEO Daniel Tassé will join a fireside chat at the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq on May 19, 2026, at 9:00 a.m. ET in New York.
A live webcast and 90-day replay will be available on the company’s investor events webpage.
DBV Technologies (NASDAQ:DBVT) reported Q1 2026 results with $229M cash as of March 31, 2026, funding operations into Q2 2027 after full exercise of PIPE warrants.
Q1 results show net loss $47.6M and increased R&D and SG&A spending as the company advances BLA submissions for VIASKIN® Peanut Patch and commercial readiness in the U.S.
DBVT (NYSE Euronext Paris) reports the total number of shares and voting rights as of March 31, 2026 under Article 223-16 of the AMF General Regulations. The company has 296,042,447 total shares and a gross total of voting rights of 296,042,447.
The net total of voting rights (excluding shares without voting rights) is 295,914,379. ISIN: FR0010417345. A PDF attachment is available for the detailed notice.